ENTITY
WuXi XDC

WuXi XDC (2268 HK)

179
Analysis
Industrials • China
WuXi XDC is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in antibody-drug conjugates (ADCs) and other bioconjugates. The company offers integrated, end-to-end services for the discovery, process development, and GMP manufacturing of bioconjugates, monoclonal antibody intermediates, and payload-linkers. WuXi XDC was founded in 2013 and is headquartered in Wuxi, China.
more
•12 Oct 2026 07:30

HK Strategy: Exposure to Europe - Who Are at Risk?

A recent surge in Eurozone sovereign yields will put pressure on some companies. The 100 largest HK companies have only 6% of their revenue from...

Logo
91 Views
Share
bearish•WuXi XDC
•27 Aug 2026 20:02

WuXi XDC (2268 HK): Synthetic Expert Call Transcript (27 Aug 2026)

Strong operational momentum is overshadowed by parent company actions: WuXi XDC delivered robust H1 2026 results with revenue growing 37.0% to...

Share
bullish•WuXi XDC
•26 Aug 2026 19:23

Aequitas: WuXi XDC Placement - Past Deals Have Been Mixed but Has Strong Momentum

WuXi AppTec (2359 HK) is looking to raise around US$300m via selling some of its stake in WuXi XDC (2268 HK). In this note, we talk about the deal...

Logo
101 Views
Share
•02 Oct 2026 09:01

HONG KONG ALPHA PORTFOLIO: (September 2026)

HK Alpha portfolio gained 2.22% in September, outperforming its benchmark by 5.36%. Since inception, the portfolio has outperformed HK indexes by...

Logo
99 Views
Share
x